A company developing a drug for depression based on synthesized compounds in hallucinogenic substances is raising $127.5 million in its initial public stock offer. . . . → Read More: Mental Health Drug Company Raises $127.5M in IPO
|
|||||
|
       
  |
A three year-old company developing protein-targeted cancer therapies with computational techniques is raising $400 million in its initial public offering of common stock. . . . → Read More: Cancer Protein Therapy Biotech Raises $400M in IPO  Comments are closed  Finance  biomedical, biotechnology, cancer, entrepreneurs, equity, investment, IPO, life sciences, mathematics, pharmaceuticals, physical sciences, university
A developer of a drug for migraine formulated as a dry powder and given as a nasal spray is raising $82.5 million in its initial public offering of common stock. . . . → Read More: Migraine Drug Developer Raises $82.5M in IPO Comments are closed Finance biomedical, chemistry, clinical trials, equity, investment, IPO, Japan, life sciences, medical device, pharmaceuticals, physical sciences
Two biotechnology enterprises in the U.S. issued their initial public stock offerings yesterday, with each company raising at least $300 million in their transactions. . . . → Read More: Two Biotechs Each Issue $300M+ IPOs Comments are closed Finance biomedical, biotechnology, clinical trials, entrepreneurs, equity, genomics, investment, IPO, life sciences, mathematics, medical device, pharmaceuticals, physical sciences
A biotechnology company developing treatments for disease and enhanced agricultural products with genome editing is raising $126 million in its initial public offering, or IPO, of common stock. . . . → Read More: Genome Editing Biotech Raises $126M in IPO Comments are closed Finance agriculture, biomedical, biotechnology, cancer, equity, genomics, investment, IPO, life sciences, pharmaceuticals 
CB Insights recently issued its annual Tech IPO Report, showing the number of initial public stock offerings in the technology industries unchanged from 2017. . . . → Read More: Infographic – Tech IPOs Flat in 2018
Moderna Therapeutics, a biotechnology enterprise developing therapies with synthetic RNA, issued its initial public stock offering, or IPO, on Thursday, raising more than $604 million. . . . → Read More: RNA Biotech Raises $604M in IPO One comment - (Comments are closed) Finance biomedical, biotechnology, equity, genomics, investment, IPO, life sciences, pharmaceuticals
A 5 year-old enterprise developing synthetic DNA for medical and agricultural chemicals, as well as data storage, is raising $70 million in its initial public stock offering. . . . → Read More: Synthetic DNA Company Raising $70 Million in IPO Comments are closed Finance biomedical, biotechnology, computer science, engineering, equity, genomics, investment, IPO, life sciences, semiconductors
A three year-old company developing treatments for cancer with engineered T-cells from the immune system raised $150 million in its initial public offering of common stock. . . . → Read More: Cancer T-Cell Start-Up Gains $150 Million in IPO Comments are closed Finance biomedical, cancer, clinical trials, entrepreneurs, equity, Europe, investment, IPO, life sciences, pharmaceuticals, U.K., university A three year-old company making new antibiotics to treat infections resistant to earlier antibiotics plans to raise some $75 million in its initial public stock offering. . . . → Read More: Multi-Drug Resistance Antibiotic Developer to Issue IPO Comments are closed Finance biomedical, biotechnology, clinical trials, entrepreneurs, equity, investment, IPO, life sciences, pharmaceuticals |
||||
|
Copyright © 2020 Technology News and Literature - All Rights Reserved Powered by WordPress & Atahualpa |
|||||